Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 in San Diego.
EMPRISE is designed to evaluate the first 5 years of empagliflozin use in the US (2014-2019) and anticipates over 200,000 patients with type 2 diabetes will be included.
In the study, empagliflozin demonstrated a 22% relative risk reduction in all-cause hospitalizations vs DPP-4 inhibitors after a mean follow-up of 5.4 months. Also, hospitalized patients treated with empagliflozin were discharged sooner than those treated with DPP-4 inhibitors (17,539 matched pairs in each treatment arm). Treatment with empagliflozin also led to significantly fewer recurrent emergency department visits and physician’s office visits compared to DPP-4 inhibitors.
Study authors also presented initial safety and efficacy data from EMPRISE at the American College of Cardiology’s 68th Annual Scientific Session & Expo in New Orleans, which showed a 42% relative risk reduction in hospitalization for heart failure or all-cause mortality with empagliflozin vs DPP-4 inhibitors. Moreover, treatment with empagliflozin was not associated with a statistically significant increased risk of bone fracture or lower leg amputation vs DPP-4 inhibitors.
These initial findings support the data from the long-term EMPAG-REG OUTCOME study, which demonstrated a 11% relative risk reduction in all-cause hospitalizations with empagliflozin in patients with type 2 diabetes and established cardiovascular disease. Also in this trial, empagliflozin decreased the relative risk of hospitalization for heart failure or cardiovascular death in patients with type 2 diabetes and established cardiovascular disease by 34%, with no imbalance with bone fractures or lower leg amputation.
Empagliflozin (Jardiance) is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor currently approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
For more information visit Jardiance.com.
This article originally appeared on MPR